Hot Stocks: Brokerages on Bharat Forge and Sun Pharma; JPMorgan see 28% upside in PNB

BofA Securities maintained its buy rating on Sun Pharma with a target of Rs 1,000. Flattish llumya trend and the company is waiting for Winlevi Rx to pick up. Sun Pharma’s global specialty revenue growth was 30% in H1FY23, this was largely aided by llumya ramp-up. Regulatory overhang continues.